Cargando…

Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells

BACKGROUND: IDH2/R140Q mutation is frequently detected in acute myeloid leukemia (AML). It contributes to leukemia via accumulation of oncometabolite D-2-HG. Therefore, mutant IDH2 is a promising target for AML. Discovery of IDH2 mutant inhibitors is in urgent need for AML therapy. METHODS: Structur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiao, Yang, Jie, Wei, Qingyun, Weng, Ling, Wu, Fei, Shi, Yun, Cheng, Xiaolan, Cai, Xueting, Hu, Chunping, Cao, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126369/ https://www.ncbi.nlm.nih.gov/pubmed/32245484 http://dx.doi.org/10.1186/s12964-020-00536-7

Ejemplares similares

Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q
por: Chen, Jiao, et al.
Publicado: (2017)

Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia
por: Wang, Dandan, et al.
Publicado: (2023)

Correction: Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia
por: Wang, Dandan, et al.
Publicado: (2023)

Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia
por: Wiseman, Daniel H., et al.
Publicado: (2016)

Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis
por: Qin, Yao, et al.
Publicado: (2023)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Mir142 loss unlocks IDH2(R140)-dependent leukemogenesis through antagonistic regulation of HOX genes
por: Marshall, A., et al.
Publicado: (2020)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
por: Sarkaria, Shawn M., et al.
Publicado: (2014)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers
por: Lee, Wen-Yuan, et al.
Publicado: (2014)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

Author Correction: Mir142 loss unlocks IDH2(R140)-dependent leukemogenesis through antagonistic regulation of HOX genes
por: Marshall, A., et al.
Publicado: (2021)

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Fiehn, Oliver, et al.
Publicado: (2016)

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
por: Gao, Mingzhao, et al.
Publicado: (2019)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
por: Cao, Meng, et al.
Publicado: (2019)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

IDH1/2 mutations in acute myeloid leukemia
por: Byun, Ja Min, et al.
Publicado: (2022)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia
por: Huang, Rui, et al.
Publicado: (2019)

Enzyme Redesign Guided by Cancer-Derived IDH1 Mutations
por: Reitman, Zachary J., et al.
Publicado: (2012)

Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
por: Bergaggio, Elisa, et al.
Publicado: (2019)

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
por: Buege, Michael J., et al.
Publicado: (2018)

The Long Non-Coding RNA IDH1-AS1 Promotes Prostate Cancer Progression by Enhancing IDH1 Enzyme Activity
por: Wu, Shuo, et al.
Publicado: (2020)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia
por: Lapierre, Marion, et al.
Publicado: (2015)

P690: IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172
por: Sakuma, Maki, et al.
Publicado: (2023)

Identification of a novel PAK1 inhibitor to treat pancreatic cancer
por: Wang, Jiaqi, et al.
Publicado: (2020)

Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oas069u717t8bno91m4vto9vt2